Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 16 03:37PM ET
123.42
Dollar change
-0.49
Percentage change
-0.39
%
Index- P/E45.69 EPS (ttm)2.70 Insider Own0.00% Shs Outstand3.38B Perf Week-1.16%
Market Cap417.57B Forward P/E29.69 EPS next Y4.16 Insider Trans- Shs Float3.38B Perf Month-6.77%
Income12.14B PEG16.32 EPS next Q0.75 Inst Own9.15% Short Float0.08% Perf Quarter16.05%
Sales33.70B P/S12.39 EPS this Y25.48% Inst Trans-2.67% Short Ratio0.56 Perf Half Y20.83%
Book/sh4.67 P/B26.44 EPS next Y22.07% ROA29.90% Short Interest2.83M Perf Year46.40%
Cash/sh1.32 P/C93.21 EPS next 5Y2.80% ROE87.44% 52W Range75.56 - 138.28 Perf YTD19.30%
Dividend Est.1.72 (1.39%) P/FCF34.63 EPS past 5Y16.48% ROI64.47% 52W High-10.75% Beta0.44
Dividend TTM1.37 (1.11%) Quick Ratio0.64 Sales past 5Y14.25% Gross Margin84.60% 52W Low63.33% ATR (14)2.66
Dividend Ex-DateMar 22, 2024 Current Ratio0.82 EPS Y/Y TTM56.16% Oper. Margin44.12% RSI (14)42.07 Volatility1.86% 1.78%
Employees63370 Debt/Eq0.25 Sales Y/Y TTM34.77% Profit Margin36.04% Recom1.94 Target Price134.96
Option/ShortYes / Yes LT Debt/Eq0.19 EPS Q/Q71.63% Payout36.03% Rel Volume0.53 Prev Close123.90
Sales Surprise4.87% EPS Surprise6.77% Sales Q/Q44.01% EarningsMay 02 BMO Avg Volume5.04M Price123.42
SMA20-3.20% SMA50-1.77% SMA20019.92% Trades Volume2,543,924 Change-0.39%
Date Action Analyst Rating Change Price Target Change
Apr-12-24Initiated BMO Capital Markets Outperform $163
Jan-23-24Initiated Morgan Stanley Overweight $120
Jan-16-24Resumed UBS Neutral
Dec-01-23Initiated Cantor Fitzgerald Overweight $120
Oct-02-23Initiated Argus Buy $110
Jul-14-23Initiated HSBC Securities Buy
Jul-15-22Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22Downgrade UBS Neutral → Sell
Jun-27-22Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22Upgrade JP Morgan Neutral → Overweight
Apr-15-24 01:39PM
10:00AM
08:43AM
Apr-14-24 03:00PM
Apr-13-24 11:16AM
04:06PM Loading…
Apr-12-24 04:06PM
07:45AM
Apr-11-24 02:15PM
Apr-10-24 05:45PM
03:41PM
03:30PM
11:52AM
09:27AM
07:15AM
06:45AM
06:10AM Loading…
06:10AM
Apr-09-24 11:42AM
06:45AM
Apr-08-24 05:35PM
02:22PM
11:23AM
09:40AM
06:31AM
06:28AM
05:55AM
Apr-07-24 07:15AM
Apr-06-24 08:47PM
08:30AM
07:45AM
Apr-05-24 12:35PM
09:27AM Loading…
Apr-04-24 09:27AM
07:30AM
04:55AM
Apr-03-24 08:02PM
12:33PM
07:24AM
06:06AM
Apr-02-24 01:00PM
09:30AM
08:51AM
06:56AM
Apr-01-24 05:50PM
04:30AM
Mar-31-24 10:15PM
06:14PM
09:31AM
08:15AM
Mar-29-24 11:04PM
01:51PM
12:49PM
11:20AM
09:30AM
05:00AM
02:00AM
Mar-28-24 06:36PM
08:13AM
Mar-27-24 06:29PM
05:47PM
Mar-26-24 01:02PM
12:59PM
12:13PM
11:58AM
11:15AM
11:13AM
10:56AM
10:35AM
05:51AM
05:10AM
Mar-25-24 08:44PM
05:50PM
01:06PM
12:22PM
10:43AM
10:00AM
09:49AM
09:07AM
08:54AM
08:42AM
07:58AM
07:21AM
07:13AM
06:25AM
06:17AM
05:59AM
03:51AM
Mar-24-24 10:58AM
09:15AM
Mar-22-24 04:42PM
12:25PM
11:53AM
10:30AM
07:42AM
07:15AM
07:08AM
05:37AM
Mar-21-24 04:44PM
04:23PM
03:35PM
02:32PM
01:12PM
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.